Cognitive, Emotional, Physical and Psychosocial Effects of Panax Quinquefolius L (NCT00527969) | Clinical Trial Compass
CompletedPhase 2
Cognitive, Emotional, Physical and Psychosocial Effects of Panax Quinquefolius L
Canada72 participantsStarted 2007-07
Plain-language summary
The purpose of this study is to determine the efficacy and safety of REMEMBER-fX (HT1001, an extract of Panax quinquefolius) in a human sample using standard clinical neuropsychological instruments and side effects rating scales.
Who can participate
Age range35 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Healthy men and women between the age of 35 - 75
* Women of child bearing capacity who agree to use an acceptable form of birth control during the trial (i.e. oral contraception, reliable use of a double-barrier method (e.g. condom and diaphragm, condom and foam, condom and sponge), IUD or tubal ligation)
* Achievement Test (WRAT-III) score greater than 70 with a reading level within normal limits as defined by a Wide Range
* Willing to adhere to the requirements of the protocol, including availability for follow-up visits
* Willing and able to sign written informed consent
Exclusion Criteria:
* Medical conditions;
* HIV/AIDS
* Malignancy (under active observation or treatment)
* Unstable cardiovascular disease (physician visit or hospitalization for unstable cardiovascular disease in the last 6 mo.)
* Renal Abnormalities (serum creatinine known to be \> 200umol/L)
* Acute or active chronic liver disease
* Diabetes
* Neurologic or psychiatric disease (progressive or currently under treatment)
* Active tuberculosis
* Multiple sclerosis
* Bleeding disorders
What they're measuring
1
Use of HT1001 will improve objective measures of psychomotor speed, sustained attention, working memory, declarative memory, and or executive skills.